Skip to content
★ Sign in to follow
GX

Guiyang Xintian Pharmaceutical Co.,Ltd. Stock: price and insider trades · China

新天药业

CN·Mcap CN¥1.9BHealth Care

Guiyang Xintian Pharmaceutical Co.,Ltd.: what insiders have been doing

Every trade that managers of Guiyang Xintian Pharmaceutical Co.,Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. From 5 November 2025 to 5 November 2026, the disclosure feed for Guiyang Xintian Pharmaceutical Co.,Ltd. logged 1 filing by 1 insider.

There is no open-market purchase to report; the filings show 1 sale worth €2.4M by 1 insider. 上海新天智药生物技术有限公司 filed the largest sale, €2.4M, on 18 December 2025.

Compared with its exchange (519 companies, median 2 filings), a count of 1 filing is below the norm. The full history, which starts in 2022, counts no purchases against 9 sales.

Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.

Insider Decl.
9
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€3M
9 ops. · all time

Who traded when

BuySale
上海新天智药生物技术有限公司1 sale

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 20,293 of 26,914 companies
34.1
score / 100
Value
29
Quality
39
FCF yld1.7%
Earn yld0.5%
EV/EBITDA38.9x
ROE0.7%
Gross mgn72%
Net mgn1.2%
Debt/EBITDA10.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥7.93
Analyst consensus
·
Income statement
RevenueCN¥749.7M
Gross profitCN¥536.6M72% margin
EBITDACN¥67M9% margin
Net incomeCN¥9.1M1.1% margin
Valuation
PER (trailing)198.3x
P/Book1.5x
Beta0.02
Balance sheet & cash
Market capCN¥1.9B
Total debtCN¥668.9M
Free Cash FlowCN¥32.1M
Debt / Equity46%
Profitability & ownership
ROE0.7%
ROA0.9%
% insiders33.2%
% institutions3.8%
Last declaration on 18 December 2025
Declarations9 total
  • ▼
    Related company / holdingExecutives
    20M CNY30SZSE
    2,190,500 shares100.0% of flowA股XSHESZSE:273000000052638400
  • ▼
    高管Executives
    193,920 CNY31SZSE
    12,000 shares17.9% of flowA股XSHESZSE:173000006007403000
  • ▼
    监事Executives
    66,470 CNY33SZSE
    3,400 shares100.0% of flowA股XSHESZSE:173000005962873100
  • ▼
    高管Executives
    870,320 CNY37SZSE
    46,000 shares82.1% of flowA股XSHESZSE:173000005962890800
  • ▼
    高管Executives
    152,400 CNY37SZSE
    8,000 shares100.0% of flowA股XSHESZSE:173000005962873540
  • ▼
    董事,高管Executives
    5M CNY33SZSE
    252,000 shares100.0% of flowA股XSHESZSE:173000005962873400
  • ▼
    监事Executives
    379,270 CNY33SZSE
    19,400 shares100.0% of flowA股XSHESZSE:173000005962873570
  • ▼
    高管Executives
    298,240 CNY37SZSE
    16,000 shares100.0% of flowA股XSHESZSE:173000005962873470
  • ▼
    董事Executives
    68,425 CNY33SZSE
    3,500 shares100.0% of flowA股XSHESZSE:173000005962873200

9 of 9 declarations

About Guiyang Xintian Pharmaceutical Co.,Ltd.

新天药业 is a company operating in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the development and production of innovative drugs.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations